Enlicitide Decanoate clinical trials
3 indexed studies · 1 currently recruiting
- RecruitingPHASE2, PHASE3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
This study is looking at a new oral medicine, enlicitide decanoate, for children and teenagers aged 6-17 with a condition called Heterozygous Familial Hypercholesterolemia (HeFH). We want to see if it's safe and helps lower high cholesterol levels.
For: Heterozygous Familial Hypercholesterolemia (HeFH)United States · Australia · Belgium - Active not recruitingPHASE3
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
This study is looking into the long-term safety and effectiveness of a new medication called Enlicitide Decanoate. It's for adults with high cholesterol who have already taken part in previous studies of this drug. The aim is to see how well it works and if it's safe over a longer period.
For: HypercholesterolemiaUnited States · Argentina · Australia - Active not recruitingPHASE3
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.
For: Arteriosclerosis · HypercholesterolaemiaUnited States · Argentina · Australia